Ftse Mib
34.600,00
-0,65%
DAX
18.726,76
-0,21%
S&P 500
5.310,89
0,05%
NASDAQ
16.808,61
0,08%
Bitcoin
69.961,34
-2,08%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Global Blood Therapeutics Inc (GBT) Global Blood Therapeutics Inc (GBT) Notizie

GBT

Global Blood Therapeutics (GBT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:GBT
DataOraFonteTitoloSimboloCompagnia
09/02/202317:04Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:GBTGlobal Blood Therapeutics Inc
17/10/202214:34Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:GBTGlobal Blood Therapeutics Inc
06/10/202222:21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GBTGlobal Blood Therapeutics Inc
05/10/202222:41Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:GBTGlobal Blood Therapeutics Inc
05/10/202222:33Edgar (US Regulatory)Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)NASDAQ:GBTGlobal Blood Therapeutics Inc
05/10/202222:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GBTGlobal Blood Therapeutics Inc
05/10/202215:00Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:GBTGlobal Blood Therapeutics Inc
16/09/202200:00GlobeNewswire Inc.GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022NASDAQ:GBTGlobal Blood Therapeutics Inc
12/09/202222:08Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:GBTGlobal Blood Therapeutics Inc
08/09/202214:00GlobeNewswire Inc.GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics ConferenceNASDAQ:GBTGlobal Blood Therapeutics Inc
29/08/202214:01Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:GBTGlobal Blood Therapeutics Inc
09/08/202214:35TipRanksGlobal Blood Therapeutics (GBT) was downgraded to a Hold Rating at SVB SecuritiesNASDAQ:GBTGlobal Blood Therapeutics Inc
08/08/202213:29Dow Jones NewsGlobal Blood Therapeutics Shares Rise Premarket After Pfizer DealNASDAQ:GBTGlobal Blood Therapeutics Inc
08/08/202213:02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:GBTGlobal Blood Therapeutics Inc
08/08/202212:45GlobeNewswire Inc.Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare HematologyNASDAQ:GBTGlobal Blood Therapeutics Inc
04/08/202222:05GlobeNewswire Inc.GBT Announces New Employment Inducement GrantsNASDAQ:GBTGlobal Blood Therapeutics Inc
03/08/202223:46Edgar (US Regulatory)Amended Statement of Beneficial Ownership (3/a)NASDAQ:GBTGlobal Blood Therapeutics Inc
03/08/202222:05GlobeNewswire Inc.GBT Announces Participation at the Wedbush PacGrow Healthcare ConferenceNASDAQ:GBTGlobal Blood Therapeutics Inc
29/07/202214:00GlobeNewswire Inc.GBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022NASDAQ:GBTGlobal Blood Therapeutics Inc
26/07/202209:01GlobeNewswire Inc.MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and OlderNASDAQ:GBTGlobal Blood Therapeutics Inc
14/07/202214:00GlobeNewswire Inc.GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in BrazilNASDAQ:GBTGlobal Blood Therapeutics Inc
13/07/202214:00GlobeNewswire Inc.The GBT Foundation Awards $250,000 in ACE Grants to Support Sickle Cell Disease Community-Based OrganizationsNASDAQ:GBTGlobal Blood Therapeutics Inc
09/07/202204:10TipRanksRBC Capital Keeps a Buy Rating on Global Blood Therapeutics (GBT)NASDAQ:GBTGlobal Blood Therapeutics Inc
05/07/202211:08TipRanksWilliam Blair Sticks to Its Buy Rating for Global Blood Therapeutics (GBT)NASDAQ:GBTGlobal Blood Therapeutics Inc
29/06/202218:55TipRanksWedbush Reiterates a Buy Rating on Global Blood Therapeutics (GBT)NASDAQ:GBTGlobal Blood Therapeutics Inc
29/06/202214:00GlobeNewswire Inc.GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell DiseaseNASDAQ:GBTGlobal Blood Therapeutics Inc
17/06/202222:05Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:GBTGlobal Blood Therapeutics Inc
16/06/202214:00GlobeNewswire Inc.NFL Running Back Tevin Coleman and Family Team Up with GBT to Share Playbook for Families Affected by Sickle Cell DiseaseNASDAQ:GBTGlobal Blood Therapeutics Inc
13/06/202214:00GlobeNewswire Inc.New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell DiseaseNASDAQ:GBTGlobal Blood Therapeutics Inc
13/06/202212:45TipRanksWedbush Thinks Global Blood Therapeutics’ Stock is Going to RecoverNASDAQ:GBTGlobal Blood Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:GBT

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
ENI
Eni
BIT
G
Generali
BIT
SPM
Saipem
BIT
BPE
Bper Banca
BIT
STMMI
ST Microelectronics
BIT
STLAM
Stellantis NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
TIT
Telecom Italia
BIT
TEN
Tenaris
BIT
RACE
Ferrari NV
BIT
LDO
Leonardo
BIT
TITR
Telecom Italia
BIT
CPR
Davide Campari
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network